Hannah Hierlmaier
Primary Care · Dover, DENPI 1134900368
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $917 and has fallen 55.6% since, to $407 in 2025.
Across 72 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$266
- AbbVie$208
- AstraZeneca$191
- Lilly USA, LLC$178
- Dexcom, Inc.$107
- Shield Therapeutics Inc$92
- plus $373 from 13 others
What the payments were for
- Food & beverage$1,415100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $266 |
| AbbVie | 9 | $208 |
| AstraZeneca | 8 | $191 |
| Lilly USA, LLC | 8 | $178 |
| Dexcom, Inc. | 6 | $107 |
| Shield Therapeutics Inc | 3 | $92 |
| Pfizer | 3 | $68 |
| Astellas Pharma US Inc | 3 | $49 |
| Amgen | 3 | $47 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Lundbeck LLC | 1 | $24 |
| Gilead | 1 | $20 |
| Novartis | 1 | $19 |
| Braeburn Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Cosette Pharmaceuticals Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Abbott | 1 | $16 |
| Indivior Inc. | 1 | $14 |
How this compares
$1,415 in reported general payments places this provider in the 75th percentile of 25 primary care providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 13 | $6,857 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $417 |
| Omeprazole | 23 | $403 |
| Ezetimibe | 13 | $368 |
| Rosuvastatin Calcium | 17 | $243 |
| Atorvastatin Calcium | 42 | $215 |
| Fluticasone Propionate | 16 | $131 |
| Amlodipine Besylate | 33 | $76 |
| Losartan Potassium | 15 | $60 |
| Lisinopril | 14 | $51 |
| Hydrochlorothiazide | 12 | $51 |
| Levothyroxine Sodium | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other primary care in Dover
- Hardi PatelDover$3K
- Florence AkouegnonWilmington$5K
- Catherine SlaughWilmington$4K
- Cynthia Lang-GroeningWilmington$3K
- Rachael OfiliNewark$2K
- Julie MbuaWilmington$1K
- Lisa StaabGeorgetown$1K
- Hanh NguyenBear$1K
- Christina RiceWilmington$618
- Teresa CohanRehoboth Beach$506
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.